KINIKSA PHARMACEUTICALS INTE (KNSA) Stock Analyst Ratings
NASDAQ:KNSA - GB00BRXB0C07 - Common Stock
34.28 USD
+0.79 (+2.36%)
34.5 USD
+0.22 (+0.64%)
ChartMill assigns a Buy % Consensus number of 87% to KNSA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 45.7. This target is 33.3% above the current price.
KNSA was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about KNSA.
In the previous month the buy percentage consensus was at a similar level.
KNSA was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-07-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-04-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-13 | Citigroup | Initiate | Buy |
| 2024-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-09-13 | Jefferies | Initiate | Buy |
| 2024-07-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-05-03 | Wells Fargo | Initiate | Overweight |
| 2024-05-01 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-24 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-01-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-26 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-03-09 | JP Morgan | Maintains | Overweight |
| 2021-12-29 | B of A Securities | Maintains | Buy |